This is a definitive federal contract awarded by the Centers for Disease Control and Prevention (CDC) to Kaiser Foundation Hospitals, doing business as Kaiser Permanente, for a prospective observational cohort study to assess the effectiveness of SARS-CoV-2 vaccines. The $55,223,588.00 contract has an ultimate completion date of December 31, 2024 and is a cost-no-fee arrangement.
The contract does not have a set-aside designation. Kaiser Permanente is collaborating with the University of Washington as a major subcontractor to execute the study. This work aligns with the CDC's efforts to monitor vaccine safety and effectiveness through the Vaccine Safety Datalink program, which Kaiser Permanente has supported under prior contracts. As a large, integrated healthcare system, Kaiser Permanente leverages its extensive patient population and electronic health records to conduct epidemiological studies and support public health initiatives for federal agencies.
Generated 8/31/24, 11:17 AM